Pharmaceutical company Sagent has announced the launch of Oxacillin for Injection, USP in three latex-free, preservative-free vial presentations.

According to Sagent, the new Oxacillin features its PreventIV Measures packaging and labeling designed to help in the reduction of medication errors.

The package insert contains detailed information about the indications, complete side effect profile and prescribing information.

The semisynthetic penicillin Oxacillin for Injection, USP is indicated in the treatment of infections caused by penicillinase producing staphylococci.

US-based Sagent focuses on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products.